La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Alzinova Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Carol Routledge

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	5.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Carol Routledge

no data

Mandato

Dr. Carol Routledge serves as the Member of Advisory Board at Cognetivity Neurosciences Ltd. since June 22, 2021. She is an experienced figure in the world of neuroscience research, having worked in the sp...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Carol Routledge	Acting CEO & Director	no data	Nessun dato	Nessun dato
Erik Kullgren	Interim Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Anders Sandberg	Chief Scientific Officer	9.6yrs	Nessun dato	0.38% SEK 741.2k
Kirsten Harting	Chief Medical Officer	less than a year	Nessun dato	Nessun dato
Sebastian Hansson	Business Development Director	1.6yrs	Nessun dato	0.016% SEK 30.9k

1.0yrs

Durata media

Gestione esperta: Il team dirigenziale di ALZ non è considerato esperto (durata media 1 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Carol Routledge	Acting CEO & Director	5.7yrs	Nessun dato	Nessun dato
Anders Sandberg	Chief Scientific Officer	13.6yrs	Nessun dato	0.38% SEK 741.2k
Anders Waas	Director	5.7yrs	Nessun dato	Nessun dato
Anders Blom	Director	3.3yrs	Nessun dato	18.98% SEK 37.4m
Julian Aleksov	Chairman of the Board	1.3yrs	Nessun dato	Nessun dato
Per-Goran Gillberg	Independent Director	4.6yrs	Nessun dato	0.28% SEK 550.8k
Clas Malmestrom	Director	9.6yrs	Nessun dato	0.022% SEK 44.2k
Jesper Dahlberg	Deputy Board Member	no data	Nessun dato	Nessun dato

5.7yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ALZ sono considerati esperti (durata media dell'incarico 5.7 anni).

Alzinova Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Alzinova AB (publ) Appoints Carol Routledge as Acting CEO, Effective August 1, 2024

Independent Director recently bought kr100k worth of stock

Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024

Alzinova AB (publ) Announces CFO Changes

Alzinova AB (publ), Annual General Meeting, May 29, 2024

Alzinova AB (Publ) Announces Retiremet of Håkan Skogström as CFO

Recent updates

New minor risk - Profitability

Alzinova AB (publ) Appoints Carol Routledge as Acting CEO, Effective August 1, 2024

Alzinova AB (Publ) Announces All Patients in the High-Dose Cohort of the Phase 1B Study

Independent Director recently bought kr100k worth of stock

Alzinova AB (Publ) Announces All Patients Have Been Recruited in the High-Dose Part of Alzinova's Phase 1B Study

Consensus EPS estimates fall by 20%

Alzinova AB (publ) Announces New External Safety Review for Phase 1b Study

First quarter 2024 earnings released

Alzinova AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 34.352689 million.

Alzinova AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 34.352689 million.

Price target increased by 20% to kr12.00

Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024

Alzinova AB (Publ) Announces All Patients in the Extension Part of the Phase 1B Study Have Received Their Last Dose of ALZ-101

Alzinova AB (publ) Announces CFO Changes

Full year 2023 earnings released: kr0.37 loss per share (vs kr0.54 loss in FY 2022)

New major risk - Revenue and earnings growth

Alzinova AB (Publ) Receives Regulatory Approval to Evaluate A Higher Dose of the Vaccine Candidate Alz-101 in the Ongoing Phase 1B Study

Alzinova AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

New major risk - Market cap size

Alzinova AB Announces Primary Analysis Confirms Positive Phase 1B Results with ALZ-101 against Alzheimer's

Alzinova AB (publ), Annual General Meeting, May 29, 2024

Alzinova AB (Publ) Announces Retiremet of Håkan Skogström as CFO

Alzinova AB (publ) Announces Positive Phase 1b Results with the Vaccine Candidate ALZ-101 Against Alzheimer's Disease

Third quarter 2023 earnings released

New minor risk - Share price stability

New major risk - Market cap size

Alzinova AB (publ) Receives Positive Response from the European Medicines Agency EMA

Second quarter 2023 earnings released

Alzinova AB (Publ) Appoints Kirsten Harting as New Chief Medical Officer, Effective from August 14, 2023

Alzinova AB (publ) Submits Request for Pre-IND Meeting with FDA and Applies for EMA Scientific Advice

Alzinova AB (Publ) Elects Julian Aleksov as Board Member and Chairman of the Board of Directors

First quarter 2023 earnings released

Director exercised options to buy kr8.7m worth of stock.

Chief Executive Officer exercised options to buy kr66k worth of stock.

Full year 2022 earnings released: kr0.40 loss per share (vs kr0.48 loss in FY 2021)

Alzinova AB (publ) Appoints Sebastian Hansson as the New Business Development Director

Alzinova AB (publ) Announces New Positive Safety Review and Interim Data from Ongoing Phase 1B Study with Vaccine Candidate ALZ-101

Alzinova AB (publ) Presents Data for its Preclinical Antibody Candidate ALZ-201 at Annual Alzheimer's Conference CTAD, Clinical Trials in Alzheimer's Disease

Alzinova AB (publ) to Report Fiscal Year 2023 Results on Feb 28, 2024

Less than half of directors are independent

Third quarter 2022 earnings released

Alzinova AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

Alzinova AB (Publ) Announces New Positive Safety Review of Its Phase 1B Study in Alzheimer's Disease

Second quarter 2022 earnings released

Alzinova AB (publ) Recruits Half of Patients for the Ongoing Phase 1B Study of the Vaccine Candidate ALZ-101

Alzinova AB (publ) Establishes Scaled-Up Manufacturing Process for ALZ-101 Ahead of Phase 2

Alzinova AB (publ) Initiates Development of a Stable Cell Line to Prepare the Monoclonal Antibody ALZ-201 for Alzheimer's Clinical Trials

Alzinova AB (publ) Initiates Development of a Stable Cell Line to Prepare the Monoclonal Antibody ALZ-201 for Alzheimer's Clinical Trials

Less than half of directors are independent

Full year 2021 earnings released: kr0.48 loss per share (vs kr0.41 loss in FY 2020)

Alzinova Improves Manufacturing Process of ALZ-101 to Meet Phase 2 Requirements

Full year 2021 earnings: EPS misses analyst expectations

Alzinova AB to Report Fiscal Year 2021 Results on Apr 14, 2022

Alzinova AB (publ) Completes Humanisation Work and Selects Lead Candidate for Monoclonal Antibody ALZ-201

Third quarter 2021 earnings released

Second quarter 2021 earnings released

First quarter 2021 earnings released

Full year 2020 earnings released: kr0.85 loss per share (vs kr0.81 loss in FY 2019)

Alzinova AB to Report Q3, 2021 Results on Oct 28, 2021

Alzinov AB Announces Drug Substance for the ALZ-101 Vaccine is Now Produced

New 90-day low: kr6.94

New 90-day low: kr7.30

Alzinova AB Announces the Study Design for the First Clinical Study with the Oligomer-Specific Therapeutic Vaccine ALZ-101 at a Scientific Congress

Third quarter earnings released

Alzinova AB (publ) Receives Positive Feedback from the Finnish Medicines Agency Fimea in View of the Upcoming Clinical Trial Application for the Alz-101 Alzheimer's Disease Vaccine

New 90-day low: kr8.68

New 90-day low - kr9.66

Earnings released

AMMINISTRATORE DELEGATO